Summary:
PHOENIX is a phase 2 trial of the safety and efficacy of bardoxolone methyl in patients with rare chronic kidney diseases:
You May Qualify if you have been diagnosed with FSGS (Focal Segmental Glomerulosclerosis)
There are 30 participating centers in the US.
The investigational drug, study-related procedures, and doctor visits will be provided at no cost to you. You may be compensated for your time and travel.
To see if you qualify, complete the online questionnaire at
PHOENIXclinicaltrial.com